Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of$ 0.37 per share. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 162.16%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.45 per share when it actually produced a loss of $0.29, delivering a surprise of 35.56%.Over the las ...